113 related articles for article (PubMed ID: 33110482)
1. Correction: Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
Chung S; Kijima K; Kudo A; Fujisawa Y; Harada Y; Taira A; Takamatsu N; Miyamoto T; Matsuo Y; Nakamura Y
Oncotarget; 2020 Oct; 11(41):3749-3750. PubMed ID: 33110482
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
Chung S; Kijima K; Kudo A; Fujisawa Y; Harada Y; Taira A; Takamatsu N; Miyamoto T; Matsuo Y; Nakamura Y
Oncotarget; 2016 Apr; 7(14):18171-82. PubMed ID: 26918358
[TBL] [Abstract][Full Text] [Related]
3. Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.
Zhu J; Wang M; Yu Y; Qi H; Han K; Tang J; Zhang Z; Zeng Y; Cao B; Qiao C; Zhang H; Hou T; Mao X
Oncotarget; 2019 Dec; 10(65):7010-7011. PubMed ID: 31857854
[TBL] [Abstract][Full Text] [Related]
4. Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Kim S; Tiedt R; Loo A; Horn T; Delach S; Kovats S; Haas K; Engstler BS; Cao A; Pinzon-Ortiz M; Mulford I; Acker MG; Chopra R; Brain C; Tomaso ED; Sellers WR; Caponigro G
Oncotarget; 2020 Apr; 11(14):1289. PubMed ID: 32292577
[TBL] [Abstract][Full Text] [Related]
5. Correction: Establishment of preclinical chemotherapy models for gastroenteropancreatic neuroendocrine carcinoma.
Ohmoto A; Suzuki M; Takai E; Rokutan H; Fujiwara Y; Morizane C; Yanagihara K; Shibata T; Yachida S
Oncotarget; 2019 Sep; 10(52):5494. PubMed ID: 31534635
[TBL] [Abstract][Full Text] [Related]
6. Correction: Calcium electroporation for treatment of sarcoma in preclinical studies.
Szewczyk A; Gehl J; Daczewska M; Saczko J; Frandsen SK; Kulbacka J
Oncotarget; 2019 Aug; 10(49):5118. PubMed ID: 31489120
[TBL] [Abstract][Full Text] [Related]
7. Correction: Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.
Gravina GL; Mancini A; Colapietro A; Marampon F; Sferra R; Pompili S; Biordi LA; Iorio R; Flati V; Argueta C; Landesman Y; Kauffman M; Shacham S; Festuccia C
Oncotarget; 2019 Oct; 10(59):6393-6395. PubMed ID: 31695847
[TBL] [Abstract][Full Text] [Related]
8. Correction: IL-17A weakens the antitumor immunity by inhibiting apoptosis of MDSCs in Lewis lung carcinoma bearing mice.
Wang J; Zhang Y; Yin K; Xu P; Tian J; Ma J; Tian X; Wang Y; Tang X; Xu H; Wang S
Oncotarget; 2022; 13():425. PubMed ID: 35198101
[TBL] [Abstract][Full Text] [Related]
9. Correction: Predictive biomarkers for disease sensitivity in lymphoma - the holy grail for HDAC inhibitors?
Eyre TA
Oncotarget; 2019 Feb; 10(17):1661. PubMed ID: 30899436
[TBL] [Abstract][Full Text] [Related]
10. Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity
Shi F; Zhang J; Liu H; Wu L; Jiang H; Wu Q; Liu T; Lou M; Wu H
Oncotarget; 2018 Mar; 9(24):17255. PubMed ID: 29683149
[TBL] [Abstract][Full Text] [Related]
11. Correction to: MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis.
Li Y; Li Y; Chen Y; Xie Q; Dong N; Gao Y; Deng H; Lu C; Wang S
Cancer Cell Int; 2018; 18():55. PubMed ID: 29652412
[TBL] [Abstract][Full Text] [Related]
12. Correction: Association of baseline inflammatory biomarkers with cancer mortality in the REGARDS cohort.
Akinyemiju T; Moore JX; Dibaba DT; Pisu M; Goodman M; Howard VJ; Safford M; Gilchrist SC; Cushman M; Long L; Judd SE
Oncotarget; 2020 Feb; 11(7):758. PubMed ID: 32133050
[TBL] [Abstract][Full Text] [Related]
13. Correction:
Holien T; Misund K; Olsen OE; Baranowska KA; Buene G; Børset M; Waage A; Sundan A
Oncotarget; 2018 Nov; 9(89):36048. PubMed ID: 30542518
[TBL] [Abstract][Full Text] [Related]
14. Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
Robb CM; Kour S; Contreras JI; Agarwal E; Barger CJ; Rana S; Sonawane Y; Neilsen BK; Taylor M; Kizhake S; Thakare RN; Chowdhury S; Wang J; Black JD; Hollingsworth MA; Brattain MG; Natarajan A
Oncotarget; 2020 Jun; 11(25):2462-2463. PubMed ID: 32637035
[TBL] [Abstract][Full Text] [Related]
15. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.
Chlenski A; Park C; Dobratic M; Salwen HR; Budke B; Park JH; Miller R; Applebaum MA; Wilkinson E; Nakamura Y; Connell PP; Cohn SL
Mol Cancer Ther; 2019 Mar; 18(3):507-516. PubMed ID: 30674566
[TBL] [Abstract][Full Text] [Related]
16. Correction: Checkpoint inhibitor induced cardiotoxicity: managing the drawbacks of our newest agents against cancer.
Brüstle K; Heidecker B
Oncotarget; 2018 Sep; 9(70):33440. PubMed ID: 30279972
[TBL] [Abstract][Full Text] [Related]
17. Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.
Lee HJ; Lee J; Jeong P; Choi J; Baek J; Ahn SL; Moon Y; Heo JD; Choi YH; Chin YW; Kim YC; Han SY
Oncotarget; 2018 Apr; 9(28):20219. PubMed ID: 29733074
[TBL] [Abstract][Full Text] [Related]
18. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
[No Abstract] [Full Text] [Related]
19. Correction: PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix.
Mann M; Kumar S; Chauhan SS; Bhatla N; Kumar S; Bakhshi S; Gupta R; Sharma A; Kumar L
Oncotarget; 2019 Jul; 10(46):4802. PubMed ID: 31413820
[TBL] [Abstract][Full Text] [Related]
20. Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor.
Hu Z; Hu Y; Liu X; Xi R; Zhang A; Liu D; Xie Q; Chen L
Oncotarget; 2018 Oct; 9(81):35283. PubMed ID: 30443295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
